Login Register Cart 0
Generic placeholder image

Current Nanomaterials

Editor-in-Chief

ISSN (Print): 2405-4615
ISSN (Online): 2405-4623

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Nanostructured Lipid Carriers: A Promising Carrier in Targeted Drug Delivery System

Author(s): Binita Palaria, Varsha Tiwari, Abhishek Tiwari*, Ramsha Aslam, Ashok Kumar, Biswa Mohan Sahoo, Manish Kumar, Sunil Singh and Suresh Kumar

Volume 8, Issue 1, 2023

Published on: 22 April, 2022

Page: [23 - 43] Pages: 21

DOI: 10.2174/2405461507666220221094925

Price: $65

conference banner
Abstract

Nanostructured Lipid Carriers (NLCs) are considered second-generation lipid-based pharmaceutical formulations in drug delivery systems. It is a more efficient drug delivery system that includes the development of a nano-particulate system, and it is superior to the conventional drug delivery system. Among all available nanoparticles, NLC has gained more attention due to its superior characteristics, such as being lipophilic, biodegradable, and biocompatible. This lipid nanoparticulate system is more advantageous over liposomes, microparticles, emulsions, and solid lipid nanoparticles. NLCs have emerged as a promising carrier for the delivery of targeted drug substances via oral, parenteral, topical, pulmonary, transdermal, and ocular routes. These nanocarriers are utilized for the delivery of both lipophilic as well as hydrophilic drugs. NLCs are composed of a matrix of physiological lipids, i.e., solid lipid and liquid lipid, emulsifiers, and water. NLCs provide an opportunity for large-scale production, ease of preparation with enhanced encapsulation, targeted efficiency, and reduced toxic effects. This review is focused on the advantages, limitations, methods of preparation, characterization, and applications of NLCs.

Keywords: Nanostructure, lipid carrier, targeted drug, delivery system, liposomes, formulations.

« Previous Next »
Graphical Abstract

[1]
Kaur K, Nautiyal U, Singh D. NLC for bioavailability enhancement. Int J Re Adv Sci Tech 2015; 2(1): 1-9.
[http://dx.doi.org/10.30750/ijrast.211]
[2]
Patil D, Pattewar S, Palival S, Patil G, Sharma S. Nanostructured lipid carriers: A novel targeted drug delivery system. Int J Re Adv Sci Tech 2020; 11(10): 4784-93.
[http://dx.doi.org/10.13040/IJPSR.0975-8232]
[3]
Patel KD, Tripathy S, Nair KS, Kesharwani R. Nano structured lipid carrier (NLC) a modern approach for topical delivery: A review. World J Pharm Pharm Sci 2013; 2(3): 921-38.
[4]
Gaba B, Fazil M, Ali A, Baboota S, Sahni JK, Ali J. Nanostructured lipid (NLCs) carriers as a bioavailability enhancement tool for oral administration. Drug Deliv 2015; 22(6): 691-700.
[http://dx.doi.org/10.3109/10717544.2014.898110] [PMID: 24670099]
[5]
Kandalkar SP, Kulkarni DA, Jagtap SS, Gorhe AA. Nanostructured lipid carrier: A novel approach to enhance solubility, bioavailability, stability and permeability of drug. J Emerg Technol Innov Res 2020; 7(5): 345-56.
[6]
Chandana VK, Gupta VN, Kanna S. Nanostructured lipid carrier: The frontiers in drug delivery. Asian J Pharm Clin Res 2019; 12(7): 8-12.
[http://dx.doi.org/10.22159/ajpcr.2019.v12i7.33595]
[7]
Chauhan I, Yasir M, Verma M, Singh AP. Nanostructured lipid carriers: A groundbreaking approach for transdermal drug delivery. Adv Pharm Bull 2020; 10(2): 150-65.
[http://dx.doi.org/10.34172/apb.2020.021] [PMID: 32373485]
[8]
Rana SS, Bhatt S, Kumar M, et al. Design and optimization of itraconazole loaded SLN for intranasal administration using central composite design. Nanosci Nanotechnol Asia 2020; 10(6): 889-91.
[http://dx.doi.org/10.2174/2210681209666191111113112]
[9]
Kumar M, Tiwari A, Basheeruddin ASM, et al. Itraconazole loaded nano-structured lipid carrier for topical ocular delivery: Optimization and evaluation. Saudi J Biol Sci 2022; 29(1): 1-10.
[http://dx.doi.org/10.1016/j.sjbs.2021.11.006]
[10]
Bhatt S, Sharma JB, Kamboj R, Kumar M, Saini V, Mandge S. Design and optimization of febuxostat-loaded nano lipid carriers using full factorial design. Turk J Pharm Sci 2021; 18(1): 61-7.
[http://dx.doi.org/10.4274/tjps.galenos.2019.32656] [PMID: 33633486]
[11]
Sharma JB, Bhatt S, Saini V, Kumar M. Pharmacokinetics and pharmacodynamics of curcumin-loaded solid lipid nanoparticles in the management of streptozotocin-induced diabetes mellitus: application of central composite design. Assay Drug Dev Technol 2021; 19(4): 262-79.
[http://dx.doi.org/10.1089/adt.2021.017] [PMID: 34000202]
[12]
Imran M, Iqubal MK, Imtiyaz K, et al. Topical nanostructured lipid carrier gel of quercetin and resveratrol: Formulation, optimization, in vitro and ex vivo study for the treatment of skin cancer. Int J Pharm 2020; 587: 119705.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119705] [PMID: 32738456]
[13]
Nandvikar YN, Lala RR, Shinde SA. Nanostructured lipid carrier: the advanced lipid carriers. Int J Pharm Sci Res 2019; 10(12): 2320-5148.
[http://dx.doi.org/10.13040/IJPSR.0975-8232]
[14]
Haider M, Abdin SM, Kamal L, Orive G. Nanostructured lipid carriers for delivery of chemotherapeutics: A review. Pharmaceutics 2020; 12(3): 1-26.
[http://dx.doi.org/10.3390/pharmaceutics12030288] [PMID: 32210127]
[15]
Sharma A, Baldi A. Nanostructured lipid carriers: A review. J Dev Drugs 2018; 7(2): 1-12.
[16]
Balamurugan K, Chintamani P. Lipid nano particulate drug delivery: An overview of the emerging trend. J Pharm Innov 2018; 7(7): 779-89.
[17]
Natarajan J, Karri V, Anindita D. Nanostructured lipid carrier: A promising drug delivery system. Glob J Nanomed 2017; 1(5): 120-5.
[http://dx.doi.org/10.19080/GJN.2017.01.555575]
[18]
Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol 2016; 44(1): 27-40.
[http://dx.doi.org/10.3109/21691401.2014.909822] [PMID: 24813223]
[19]
Upreti T, Senthil V. NLC system for the treatment of skin diseases: A review. JSM Nanotechnol Nanomed 2017; 5(3): 1-6.
[20]
Khosa A, Reddi S, Saha RN. Nanostructured lipid carriers for site-specific drug delivery. Biomed Pharmacother 2018; 103: 598-613.
[http://dx.doi.org/10.1016/j.biopha.2018.04.055] [PMID: 29677547]
[21]
Shah NV, Seth AK, Balaraman R, Aundhia CJ, Maheshwari RA, Parmar GR. Nanostructured lipid carriers for oral bioavailability enhancement of raloxifene: Design and in vivo study. J Adv Res 2016; 7(3): 423-34.
[http://dx.doi.org/10.1016/j.jare.2016.03.002] [PMID: 27222747]
[22]
Tran TH, Ramasamy T, Truong DH, Choi HG, Yong CS, Kim JO. Preparation and characterization of fenofibrate-loaded nanostructured lipid carriers for oral bioavailability enhancement. AAPS PharmSciTech 2014; 15(6): 1509-15.
[http://dx.doi.org/10.1208/s12249-014-0175-y] [PMID: 25035071]
[23]
Son GH, Na YG, Huh HW, et al. Systemic design and evaluation of ticagrelor-loaded nanostructured lipid carriers for enhancing bioavailability and antiplatelet activity. Pharmaceutics 2019; 11(5): 1-18.
[http://dx.doi.org/10.3390/pharmaceutics11050222] [PMID: 31071977]
[24]
Shi F, Wei Z, Zhao Y, Xu X. NLC loaded with baicalin: an efficient carrier for enhanced antidiabetic effects. Pharmacogn Mag 2016; 12(47): 198-202.
[http://dx.doi.org/10.4103/0973-1296.186347] [PMID: 27601850]
[25]
Zhou J, Zhou D. Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers. Drug Des Devel Ther 2015; 9: 5269-75.
[http://dx.doi.org/10.2147/DDDT.S90016] [PMID: 26425076]
[26]
Huang W, Dou H, Wu H, Wang H, Huang L. Preparation and characterisation of nobiletin-loaded nanostructured lipid carriers. J Nanomater 2017; 2017(54): 1-10.
[http://dx.doi.org/10.1155/2017/2898342]
[27]
Gadad PA, Tigadi GS, Dandagi MP, Mastiholimath SV, Bolmal BU. Rosuvastatin loaded nanostructured lipid carrier: For enhancement of oral bioavailability. Indian J Pharm Educ Res 2016; 50(4): 605-11.
[http://dx.doi.org/10.5530/ijper.50.4.13]
[28]
Anwar W, Dawaba HM, Afouna MI, Samy AM, Rashed MH, Abdelaziz AE. Enhancing the oral bioavailability of candesartan cilexetil loaded nanostructured lipid carriers: In vitro characterization and absorption in rats after oral administration. Pharmaceutics 2020; 12(11): 1-19.
[http://dx.doi.org/10.3390/pharmaceutics12111047] [PMID: 33142816]
[29]
Teng Z, Yu M, Ding Y, et al. Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability. Int J Nanomedicine 2018; 14: 119-33.
[http://dx.doi.org/10.2147/IJN.S186899] [PMID: 30613141]
[30]
Yu Q, Hu X, Ma Y, et al. Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus. Drug Deliv 2016; 23(4): 1469-75.
[http://dx.doi.org/10.3109/10717544.2016.1153744] [PMID: 27187522]
[31]
Dong Z, Iqbal S, Zhao Z. Preparation of ergosterol-loaded nanostructured lipid carriers for enhancing oral bioavailability and antidiabetic nephropathy effects. AAPS PharmSciTech 2020; 21(2): 64.
[http://dx.doi.org/10.1208/s12249-019-1597-3] [PMID: 31932990]
[32]
Singh A, Neupane YR, Mangla B, Kohli K. Nanostructured lipid carriers for oral bioavailability enhancement of exemestane: Formulation design, in vitro, ex vivo, and in vivo studies. J Pharm Sci 2019; 108(10): 3382-95.
[http://dx.doi.org/10.1016/j.xphs.2019.06.003] [PMID: 31201904]
[33]
Managuli RS, Wang JT, Faruqu FN, et al. Asenapine maleate-loaded nanostructured lipid carriers: optimization and in vitro, ex vivo and in vivo evaluations. Nanomedicine (Lond) 2019; 14(7): 889-910.
[http://dx.doi.org/10.2217/nnm-2018-0289] [PMID: 30874464]
[34]
Elmowafy M, Ibrahim HM, Ahmed MA, Shalaby K, Salama A, Hefesha H. Atorvastatin-loaded nanostructured lipid carriers (NLCs): Strategy to overcome oral delivery drawbacks. Drug Deliv 2017; 24(1): 932-41.
[http://dx.doi.org/10.1080/10717544.2017.1337823] [PMID: 28617150]
[35]
Elmowafy M, Samy A, Raslan MA, et al. Enhancement of bioavailability and pharmacodynamic effects of thymoquinone via NLC(NLC) formulation. AAPS PharmSciTech 2015; 17(3): 663-72.
[http://dx.doi.org/10.1208/s12249-015-0391-0] [PMID: 26304932]
[36]
Anuradha K, Kumar MS. Development of Lacidipine loaded nanostructured lipid carriers (NLCs) for bioavailability enhancement. Int J Med Res Pharm Sci 2014; 2(2): 50-7.
[37]
Fang CL, Al-Suwayeh SA, Fang JY. Nanostructured lipid carriers (NLCs) for drug delivery and targeting. Recent Pat Nanotechnol 2013; 7(1): 41-55.
[http://dx.doi.org/10.2174/187221013804484827] [PMID: 22946628]
[38]
Selvamuthukumar S, Velmurugan R. Nanostructured lipid carriers: A potential drug carrier for cancer chemotherapy. Lipids Health Dis 2012; 11(1): 159.
[http://dx.doi.org/10.1186/1476-511X-11-159] [PMID: 23167765]
[39]
Jiang H, Pei L, Liu N, Li J, Li Z, Zhang S. Etoposide-loaded nanostructured lipid carriers for gastric cancer therapy. Drug Deliv 2016; 23(4): 1379-82.
[http://dx.doi.org/10.3109/10717544.2015.1048491] [PMID: 26162024]
[40]
Chen Y, Pan L, Jiang M, Li D, Jin L. Nanostructured lipid carriers enhance the bioavailability and brain cancer inhibitory efficacy of curcumin both in vitro and in vivo. Drug Deliv 2016; 23(4): 1383-92.
[http://dx.doi.org/10.3109/10717544.2015.1049719] [PMID: 26066035]
[41]
Nordin N, Yeap SK, Rahman HS, et al. In vitro cytotoxicity and anticancer effects of citral NLCon MDA MBA-231 human breast cancer cells. Sci Rep 2019; 9(1): 1-19.
[http://dx.doi.org/10.1038/s41598-018-38214-x] [PMID: 30626917]
[42]
Ding X, Xu X, Zhao Y, et al. Tumor targeted NLCco-delivering paclitaxel and indocyanine green for laser triggered synergetic therapy of cancer. RSC Adv 2017; 7(56): 35086-95.
[http://dx.doi.org/10.1039/C7RA06119F]
[43]
Foong JN, Selvarajah GT, Rasedee A, et al. Zerumbone-loaded nlc induces apoptosis of canine mammary adenocarcinoma cells. BioMed Res Int 2018.
[http://dx.doi.org/10.1155/2018/8691569]
[44]
Zhang G, Liu F, Jia E, Jia L, Zhang Y. Folate-modified, cisplatin-loaded lipid carriers for cervical cancer chemotherapy. Drug Deliv 2016; 23(4): 1393-7.
[http://dx.doi.org/10.3109/10717544.2015.1054052] [PMID: 26165422]
[45]
Almousallam M, Moia C, Zhu H. Development of NLC for dacarbazine delivery. Int Nano Lett 2015; 5: 241-8.
[http://dx.doi.org/10.1007/s40089-015-0161-8]
[46]
Sun M, Nie S, Pan X, Zhang R, Fan Z, Wang S. Quercetin-nanostructured lipid carriers: characteristics and anti-breast cancer activities in vitro. Colloids Surf B Biointerfaces 2014; 113: 15-24.
[http://dx.doi.org/10.1016/j.colsurfb.2013.08.032] [PMID: 24060926]
[47]
Bais N, Birthare A, Dubey A, Choudhary GP. Nano lipid carrier system in cosmetic dermal preparation: A review. Int J Pharm Life Sci 2016; 7(9): 5177-84.
[48]
Rajinikanth PS, Chellian J. Development and evaluation of nanostructured lipid carrier-based hydrogel for topical delivery of 5-fluorouracil. Int J Nanomedicine 2016; 11: 5067-77.
[http://dx.doi.org/10.2147/IJN.S117511] [PMID: 27785014]
[49]
Phatak A, Chaudhari PD. Development and evaluation of Nanostructured Lipid Carrier (NLC) based topical delivery of an anti-inflammatory drug. J Pharm Res 2013; 7(8): 677-85.
[http://dx.doi.org/10.1016/j.jopr.2013.08.020]
[50]
Nagaich U, Gulati N. Nanostructured lipid carriers (NLC) based controlled release topical gel of clobetasol propionate: Design and in vivo characterization. Drug Deliv Transl Res 2016; 6(3): 289-98.
[http://dx.doi.org/10.1007/s13346-016-0291-1] [PMID: 27072979]
[51]
Sachan AK, Gupta A, Arora M. Formulation and characterization of Nanostructured Lipid Carrier (NLC) based gel for topical delivery of etoricoxib. J Drug Deliv Ther 2016; 6(2): 4-13.
[http://dx.doi.org/10.22270/jddt.v6i2.1222]
[52]
Geng Q, Zhao Y, Wang L, Xu L, Chen X, Han J. Development and evaluation of astaxanthin as nanostructure lipid carriers in topical delivery. AAPS PharmSciTech 2020; 21(8): 318.
[http://dx.doi.org/10.1208/s12249-020-01822-w] [PMID: 33175290]
[53]
Zhao J, Piao X, Shi X, Si A, Zhang Y, Feng N. Podophyllotoxin-loaded nanostructured lipid carriers for skin targeting: In vitro and in vivo studies. Molecules 2016; 21(11): 1-11.
[http://dx.doi.org/10.3390/molecules21111549] [PMID: 27869698]
[54]
Khurana S, Jain NK, Bedi PMS. Development and characterization of a novel controlled release drug delivery system based on nanostructured lipid carriers gel for meloxicam. Life Sci 2013; 93(21): 763-72.
[http://dx.doi.org/10.1016/j.lfs.2013.09.027] [PMID: 24113071]
[55]
Wang W, Chen L, Huang X, Shao A. Preparation and characterization of minoxidil loaded nanostructured lipid carriers. AAPS PharmSciTech 2017; 18(2): 509-16.
[http://dx.doi.org/10.1208/s12249-016-0519-x] [PMID: 27120090]
[56]
Motawea A, Borg T, Abd El-Gawad AEH. Topical phenytoin nanostructured lipid carriers: Design and development. Drug Dev Ind Pharm 2018; 44(1): 144-57.
[http://dx.doi.org/10.1080/03639045.2017.1386204] [PMID: 28956451]
[57]
Fan X, Chen J, Shen Q. Docetaxel-nicotinamide complex-loaded nanostructured lipid carriers for transdermal delivery. Int J Pharm 2013; 458(2): 296-304.
[http://dx.doi.org/10.1016/j.ijpharm.2013.10.036] [PMID: 24177313]
[58]
Gaba B, Fazil M, Khan S, Ali A, Baboota S, Ali J. NLC system for topical delivery of terbinafine hydrochloride. Bull Fac Pharm Cairo Univ 2015; 53(2): 147-59.
[http://dx.doi.org/10.1016/j.bfopcu.2015.10.001]
[59]
Madan JR, Khobaragade S, Dua K, Awasthi R. Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast. Dermatol Ther 2020; 33(3): e13370.
[http://dx.doi.org/10.1111/dth.13370] [PMID: 32250507]
[60]
Raj SB, Chandrasekhar KB, Reddy KB. Formulation, in-vitro and in-vivo pharmacokinetic evaluation of simvastatin NLC loaded transdermal drug delivery system. Future J Pharm Sci 2019; 5(9): 1-14.
[http://dx.doi.org/10.1186/s43094-019-0008-7]
[61]
Mendes IT, Ruela ALM, Carvalho FC, Freitas JTJ, Bonfilio R, Pereira GR. Development and characterization of nanostructured lipid carrier-based gels for the transdermal delivery of donepezil. Colloids Surf B Biointerfaces 2019; 177: 274-81.
[http://dx.doi.org/10.1016/j.colsurfb.2019.02.007] [PMID: 30763792]
[62]
Liu D, Liu Z, Wang L, Zhang C, Zhang N. Nanostructured lipid carriers as novel carrier for parenteral delivery of docetaxel. Colloids Surf B Biointerfaces 2011; 85(2): 262-9.
[http://dx.doi.org/10.1016/j.colsurfb.2011.02.038] [PMID: 21435845]
[63]
Zheng D, Dai W, Zhang D, et al. In vivo studies on the oridonin-loaded nanostructured lipid carriers. Drug Deliv 2012; 19(6): 286-91.
[http://dx.doi.org/10.3109/10717544.2012.704096] [PMID: 22928767]
[64]
Jia L, Zhang D, Li Z, et al. Nanostructured lipid carriers for parenteral delivery of silybin: Biodistribution and pharmacokinetic studies. Colloids Surf B Biointerfaces 2010; 80(2): 213-8.
[http://dx.doi.org/10.1016/j.colsurfb.2010.06.008] [PMID: 20621458]
[65]
Feng F, Zheng D, Zhang D, et al. Preparation, characterization and biodistribution of nanostructured lipid carriers for parenteral delivery of bifendate. J Microencapsul 2011; 28(4): 280-5.
[http://dx.doi.org/10.3109/02652048.2011.559285] [PMID: 21545318]
[66]
Liu K, Sun J, Wang Y, He Y, Gao K, He Z. Preparation and characterization of 10-hydroxy-camptothecin loaded nanostructured lipid carriers. Drug Dev Ind Pharm 2008; 34(5): 465-71.
[http://dx.doi.org/10.1080/03639040701662230] [PMID: 18473227]
[67]
Iqbal MA, Md S, Sahni JK, Baboota S, Dang S, Ali J. Nanostructured lipid carriers system: recent advances in drug delivery. J Drug Target 2012; 20(10): 813-30.
[http://dx.doi.org/10.3109/1061186X.2012.716845] [PMID: 22931500]
[68]
Li X, Nie SF, Kong J, Li N, Ju CY, Pan WS. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm 2008; 363(1-2): 177-82.
[http://dx.doi.org/10.1016/j.ijpharm.2008.07.017] [PMID: 18706987]
[69]
Luo Q, Zhao J, Zhang X, Pan W. Nanostructured lipid carrier (NLC) coated with Chitosan Oligosaccharides and its potential use in ocular drug delivery system. Int J Pharm 2011; 403(1-2): 185-91.
[http://dx.doi.org/10.1016/j.ijpharm.2010.10.013] [PMID: 20951778]
[70]
Balguri SP, Adelli GR, Majumdar S. Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues. Eur J Pharm Biopharm 2016; 109: 224-35.
[http://dx.doi.org/10.1016/j.ejpb.2016.10.015] [PMID: 27793755]
[71]
Araújo J, Nikolic S, Egea MA, Souto EB, Garcia ML. Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye. Colloids Surf B Biointerfaces 2011; 88(1): 150-7.
[http://dx.doi.org/10.1016/j.colsurfb.2011.06.025] [PMID: 21764568]
[72]
Liu R, Liu Z, Zhang C, Zhang B. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: Improving in vivo ocular bioavailability. J Pharm Sci 2012; 101(10): 3833-44.
[http://dx.doi.org/10.1002/jps.23251] [PMID: 22767401]
[73]
Fu T, Yi J, Lv S, Zhang B. Ocular amphotericin B delivery by chitosan-modified nanostructured lipid carriers for fungal keratitis-targeted therapy. J Liposome Res 2017; 27(3): 228-33.
[http://dx.doi.org/10.1080/08982104.2016.1224899] [PMID: 27601177]
[74]
Üstündağ-Okur N, Gökçe EH, Bozbıyık Dİ Eğrilmez S, Ertan G, Özer Ö. Novel nanostructured lipid carrier-based inserts for controlled ocular drug delivery: Evaluation of corneal bioavailability and treatment efficacy in bacterial keratitis. Expert Opin Drug Deliv 2015; 12(11): 1791-807.
[http://dx.doi.org/10.1517/17425247.2015.1059419] [PMID: 26159181]
[75]
Seyfoddin A, Al-Kassas R. Development of solid lipid nanoparticles and nanostructured lipid carriers for improving ocular delivery of acyclovir. Drug Dev Ind Pharm 2013; 39(4): 508-19.
[http://dx.doi.org/10.3109/03639045.2012.665460] [PMID: 22424312]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy